Bausch Health Companies Inc. logo

Bausch Health Companies Inc.

BHC

NYSEHealthcareDrug Manufacturers - Specialty & Generic

Previous close

$6.44

−$0.37 · -5.43%

Aug 21, 4:00 PM ET

BHC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

100

Deep Value

Momentum

28

Weakening

Sentiment

56

Mixed

Risk resilience

45

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
CA
CEO
Thomas J. Appio
Listed since
Mar 29, 1994
Employees
20,300

Market position

Day range

Current $6.44

52-week range

Current $6.44

Open
$6.78
Previous close
$6.81
Volume
3.97M
1.35× average
Average volume
2.93M
Average daily volume
Market cap
2.41B USD
Beta
0.38
Market reference 1
50-day average
$5.372
+19.88% above average
200-day average
$5.8575
+9.94% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
22.46B USD
P/E (TTM)
-2.18×
P/B (TTM)
-1.36×
P/S (TTM)
0.22×
EV / EBITDA
7.07×
Earnings yield
6.09%
Free cash flow yield
38.91%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
71.82%
Operating margin
25.44%
Net margin
-10.12%
Return on equity
-28.39%
Return on assets
0.60%
Return on invested capital
3.18%

Financial health

Debt / equity
-11.73×
Current ratio
1.47×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends80%47%14%-20%Gross margin, FY2021: 71.61%Gross margin, FY2022: 70.90%Gross margin, FY2023: 70.78%Gross margin, FY2024: 71.10%Gross margin, FY2025: 70.65%Operating margin, FY2021: 5.34%Operating margin, FY2022: 5.59%Operating margin, FY2023: 11.00%Operating margin, FY2024: 16.06%Operating margin, FY2025: 21.28%Net margin, FY2021: -11.24%Net margin, FY2022: -2.77%Net margin, FY2023: -6.76%Net margin, FY2024: -0.48%Net margin, FY2025: 1.53%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 71.61%. Gross margin FY2022 70.90%. Gross margin FY2023 70.78%. Gross margin FY2024 71.10%. Gross margin FY2025 70.65%. Operating margin FY2021 5.34%. Operating margin FY2022 5.59%. Operating margin FY2023 11.00%. Operating margin FY2024 16.06%. Operating margin FY2025 21.28%. Net margin FY2021 -11.24%. Net margin FY2022 -2.77%. Net margin FY2023 -6.76%. Net margin FY2024 -0.48%. Net margin FY2025 1.53%.

Income trends

Revenue

10.27B USD+6.66%

Operating income

2.19B USD+41.33%

Net income

157M USD+203M USD
Income trends across reported periods11.39B USD6.9B USD2.42B USD−2.07B USDRevenue, FY2021: 8.43B USDRevenue, FY2022: 8.12B USDRevenue, FY2023: 8.76B USDRevenue, FY2024: 9.63B USDRevenue, FY2025: 10.27B USDOperating income, FY2021: 450M USDOperating income, FY2022: 454M USDOperating income, FY2023: 963M USDOperating income, FY2024: 1.55B USDOperating income, FY2025: 2.19B USDNet income, FY2021: −948M USDNet income, FY2022: −225M USDNet income, FY2023: −592M USDNet income, FY2024: −46M USDNet income, FY2025: 157M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 8.43B USD. Revenue FY2022 8.12B USD. Revenue FY2023 8.76B USD. Revenue FY2024 9.63B USD. Revenue FY2025 10.27B USD. Operating income FY2021 450M USD. Operating income FY2022 454M USD. Operating income FY2023 963M USD. Operating income FY2024 1.55B USD. Operating income FY2025 2.19B USD. Net income FY2021 −948M USD. Net income FY2022 −225M USD. Net income FY2023 −592M USD. Net income FY2024 −46M USD. Net income FY2025 157M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue10.27B USD9.63B USD8.76B USD8.12B USD8.43B USD
Cost of goods sold3.01B USD2.78B USD2.56B USD2.36B USD2.39B USD
Gross profit7.25B USD6.84B USD6.2B USD5.76B USD6.04B USD
Research and development629M USD634M USD604M USD530M USD473M USD
Selling, general, and administrative3.44B USD3.28B USD2.9B USD2.53B USD2.49B USD
Operating expenses5.07B USD5.3B USD5.24B USD5.31B USD5.59B USD
Interest income48M USD33M USD26M USD14M USD7M USD
Interest expense1.6B USD1.39B USD1.33B USD1.46B USD1.43B USD
Depreciation and amortization1.21B USD1.27B USD1.26B USD1.39B USD1.55B USD
Operating income2.19B USD1.55B USD963M USD454M USD450M USD
Net income157M USD−46M USD−592M USD−225M USD−948M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-3.53%
11 comparable reports
Latest EPS result
1.26
Estimate 0.96 · Beat by 31.25%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.731.320.920.51Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 19, 2025: actual 1.15, estimate 1.65, surprise -30.30%, Miss. Q2 2025, reported Apr 30, 2025: actual 0.59, estimate 0.83, surprise -28.92%, Miss. Q3 2025, reported Jul 30, 2025: actual 0.9, estimate 0.97, surprise -7.22%, Miss. Q4 2025, reported Oct 29, 2025: actual 1.16, estimate 1.07, surprise +8.41%, Beat. Q1 2026, reported Feb 18, 2026: actual 1.08, estimate 1.21, surprise -10.74%, Miss. Q2 2026, reported Apr 29, 2026: actual 0.78, estimate 0.81, surprise -3.70%, Miss. Q3 2026, reported Jul 29, 2026: actual 1.26, estimate 0.96, surprise +31.25%, Beat. Q4 2026, reported Oct 28, 2026: actual —, estimate 1.19, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.93B2.67B2.41B2.15BQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 19, 2025: actual 2.56B USD, estimate 2.29B USD, surprise +11.88%, Beat. Q2 2025, reported Apr 30, 2025: actual 2.26B USD, estimate 2.48B USD, surprise -8.88%, Miss. Q3 2025, reported Jul 30, 2025: actual 2.53B USD, estimate 2.58B USD, surprise -2.07%, Miss. Q4 2025, reported Oct 29, 2025: actual 2.68B USD, estimate 2.71B USD, surprise -1.05%, Miss. Q1 2026, reported Feb 18, 2026: actual 2.79B USD, estimate 2.73B USD, surprise +2.12%, Beat. Q2 2026, reported Apr 29, 2026: actual 2.47B USD, estimate 2.37B USD, surprise +4.29%, Beat. Q3 2026, reported Jul 29, 2026: actual 2.81B USD, estimate 2.59B USD, surprise +8.74%, Beat. Q4 2026, reported Oct 28, 2026: actual —, estimate 2.79B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$9.83

52.64% upside
Past 12 months12-month forecastHigh $16.00Average $9.83Low $8.00

Recent analyst actions

5 institutions
BarclaysmaintainEqual Weight
Piper SandlerdowngradeNeutralUnderweight

BHC news

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$1.28

2010 complete year+156.0% since 2006

Corporate action history

Dividend

Ex-dividend Nov 10, 2010

$1.00

Quarterly

Record Nov 15, 2010 · Payment Dec 22, 2010

Dividend

Ex-dividend Aug 30, 2010

$0.095

Quarterly

Record Sep 1, 2010 · Payment Oct 4, 2010

Dividend

Ex-dividend May 28, 2010

$0.095

Quarterly

Record Jun 2, 2010 · Payment Jul 5, 2010

Dividend

Ex-dividend Mar 4, 2010

$0.09

Quarterly

Record Mar 8, 2010 · Payment Apr 5, 2010

Dividend

Ex-dividend Nov 30, 2009

$0.09

Quarterly

Record Dec 2, 2009 · Payment Jan 4, 2010

Dividend

Ex-dividend Aug 28, 2009

$0.09

Quarterly

Record Sep 1, 2009 · Payment Oct 5, 2009

BHC peers

ETFs holding BHC

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research BHC

research.disclaimer